Used in scans for known or suspected coronary artery disease Assessment of left ventricular function (left ventricular ejection fraction and wall motion). Sold as Myoview, Myoview 30ML. Every FDA application for this active ingredient.
As of Nov 22, 2026, FDA lists 1 application for Technetium TC-99M tetrofosmin kit (sold as Myoview, Myoview 30ML), first approved Feb 9, 1996, with 2 new uses approved and 0 published complete response letters.
| Approved | Application | Sponsor | Supplements | Marketing |
|---|---|---|---|---|
| Feb 9, 1996 | Myoview, Myoview 30MLNDA 20372 · New molecular entity | Medi-Physics | 20 | Marketed |
Applications, approvals and products come from FDA's Drugs@FDA data files, refreshed weekly, grouped by active ingredient as FDA spells it. Complete response letters are FDA's published letters. Medicare spending is CMS's Part D and Part B dashboard, matched to this ingredient by generic name; shortages are FDA's shortage list, matched by application number; clinical trials are ClinicalTrials.gov studies naming the ingredient as an intervention, refreshed daily; safety programs are FDA's REMS list, matched by application number or, for shared programs, by ingredient. Mechanisms, targets, withdrawals and boxed warnings are from ChEMBL (EMBL-EBI, CC BY-SA 3.0), matched by ingredient name. How trials ended is TrialPanorama's classification of ClinicalTrials.gov records (Wang et al. 2025, Apache-2.0), matched by the intervention name each trial registered. Drugs@FDA